PDCD1 and mesothelioma: A total of 57 patients with mesothelioma were enrolled, and of those naïve to treatment with anti-PD-L1 or anti-PD-1 therapy, the ORR was 17.1% (90% CI 8.3–29.7%), with a median PFS of 5.5 months (Table 1).